



Neutrocheck®

Safer care and peace of mind for people living with cancer

52North creates digitally integrated clinical decision support tools. Their solutions bring together biochemical, biophysical and digital biomarkers. 52North endeavour to help people live better lives and do this through innovating, collaborating, and using cutting-edge technology that centres itself across a broad spectrum of its engagement – whether they are people living with disease, carers, doctors, paramedics or nurses.

Overview

- 52North create affordable, cutting-edge technology to bring healthcare closer to patients.
- 52North's patented user-centric technology enables:
 1. Rapid low-cost measurement of cells and solutes from a single sample
 2. Automatic release of buffers
 3. AI-driven triage by integration with a digital platform
- Vision is to become a market-leader in clinical decision support tools.
- The market opportunity for remote monitoring solutions in oncology is ripe!

Neutropenic Sepsis (NS)

- Neutropenic Sepsis (NS) is the most fatal side-effect of chemotherapy treatment.
- Patients with NS must receive intravenous antibiotics within 1 hour. Every hour's delay increases risk of death by 8%.
- There is currently no method of understanding a person's risk of neutropenic sepsis outside of hospital.
- This leads to two major problems:
 1. 1 in 2 patients was never at risk of NS and may not have needed to come into A&E and/or consume antibiotics.
 2. 1 in 2 patients do not receive antibiotics within the recommended timeline, risking lives.
- **52North's Neutrocheck addresses both of these problems.**

Neutrocheck

- Neutrocheck is a low-cost finger prick blood test and digital platform that provides a rapid and reliable result at-home, helping doctors to identify patients at risk of neutropenic sepsis.
- Neutrocheck reinvents the care pathway, making it safer and more effective.
 1. What it does: Rapidly and remotely identify cancer patients at risk of neutropenic sepsis (NS), which is the most fatal side-effect of chemotherapy treatment.
 2. The key impact: Prevent 250,000 unnecessary ER visits; Save lives; Improve patient outcomes and quality of life.
 3. The buyers: Target buyers are also investors – a leading U.S. medical centre & the UK's largest healthcare provider.
- Two patents in internationalisation phase through PCT.

Team

Led by a strong, multidisciplinary and experienced team

52North

Umalma Malik Ahmad LLB MPhil
Chief Executive Officer
MT 35/35 Women in Business,
Lawyer & Pharma M&A Transactor

Dr Mirela Crispin MSc DPhil
Chief Digital Officer
Data Scientist, AI Expertise,
Assistant Prof at Univ. of Cambridge

Dr Saif Ahmad MD-PhD FRCS
Chief Scientific & Medical Officer
Cancer Clinician, Biomedical Researcher,
NHS Clinical Entrepreneur

Dr Nicole Weckman BAsc MEng PhD
Chief Technology Officer
Biosensor Engineer, Chair in Global
Engineering, University of Toronto

Tim Dwyer BSc MBA
Technology Advisor
Chartered biologist, experienced in IVDs
from concept to market, former Dx CTO

Dr Ama Frimpong MEng PhD
Head of Product Development
IET Woman Engineer of 2022,
Mechanical Engineer

Jason Higgins BSc CIM
Head of Digital Development
Software development and digital
strategy expert, former tech CTO

Dr Amanda Wooding
Non-Executive Director
Deputy Head of Life Sciences,
Cambridge Enterprise (Investor), On
boards of multiple health-tech SMEs

Prof Sir Leszek Borysiewicz
Non-Executive Director
Chair of Cancer Research UK,
Vice-Chancellor, Uni. of Cambridge &
CEG, MRC

John Jeans CBE
Advisor
Experienced Chair and Exec in
diagnostics and digital health

Fundraising

- 52North are raising \$5-6m for their seed round to get to first sales in U.S. & Europe.
- 52North have received \$4.4m funding to date (\$2.8m non-dilutive; \$1.6m equity) from InnovateUK, Accelerated Access Collaborative and National Institute for Health Research.
- Key investors include Macmillan cancer support, University of Cambridge, Crista Galli Ventures, KHP Ventures, Milltrust International & Cedars Sinai.

Use of Funds

1. Launch, scale up and sell Neurocheck solution.
 - Receive key regulatory approvals (U.S., Europe and UK)
 - Target \$m+ ARR in 2025
2. Pipeline build

Who is the buyer:
Two-Phase
Business Model
for the U.S.

**Phase 1:
Healthcare
Providers**

- **Sell to healthcare providers**
- **Reimbursed** under Remote Patient Monitoring codes
- **Value Proposition:** reduced ER visits

**Phase 2:
Insurers**

- **Sell directly to insurers**, with Neurocheck provided to healthcare providers for distribution to patients, or incorporated within insurance bundle
- **Value Proposition:** reduced ER visits + reduced length of stay; avoid costs of hospital visits & avoid penalties from local govt in certain states e.g. CA
- Discussions ongoing with Anthem to analyse retrospective data and potential impact on insurer costs

Impact

- 250,000 unnecessary ER visits prevented.
- Reduced length of stay in hospitals.
- 2000 lives saved.
- \$100s of millions in efficiency savings.



About Milltrust International

With its mantra of “Sustainable Prosperity”, Milltrust International Group is a global investment organisation making sustainable impact investments in the biggest themes of our generation: climate change, the demand for food and protein, the future of medical technology, and the rise of the developing world.

Over the past decade, Milltrust has assembled a highly experienced team of leading industry professionals focused exclusively on providing investment management expertise on both public and private markets.

Milltrust’s private investments consist of a plethora of science-backed early-stage disruptive companies in the space of climate impact, healthcare, and agriculture. By drawing on the experience of investment bankers, asset managers, healthcare professionals, and agronomists, our diversified assets have pioneered breakthrough technology in environmental management, medical diagnostics, and animal genetics and welfare with the aim of delivering sustainable solutions an ever-growing and increasingly ageing global population.

About The British Innovation Fund II

The British Innovation Fund II follows on from the success of The British Innovation Fund I, investing into high potential companies with a focus on agri-tech, the future of healthcare, climate impact, and alternative protein, where incontrovertible science is at the core of the commercial proposition.

More Information

Milltrust International UK

6 Stratton Street
London W1J 8LD
United Kingdom

+44 (0)20 8123 8316

info@milltrust.com

Milltrust International Singapore

77B Tras Steet
Singapore 079016
Singapore

+65 6225 3052

info@milltrust.com

Signatory of:



Disclaimer

For professional investors only. This document is strictly private and confidential and is meant as guidance and information only. It is issued by Milltrust International LLP which is authorised and regulated by the Financial Conduct Authority in the United Kingdom. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. Milltrust Ventures Pte Ltd is a subsidiary of Milltrust International Group (Singapore) Pte. Ltd and is registered with the Monetary Authority of Singapore as a Venture Capital Fund Management Company (VCFM). The content in this document is for informational purposes only and does not constitute legal, tax, investment, financial, or other advice. Nothing contained in this document constitutes a solicitation, recommendation, endorsement, or offer by Milltrust International LLP or any of its affiliates to buy or sell any securities or other financial instruments. No such solicitation or offer is made in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this document is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the document constitutes professional and/or financial advice, nor does any information on the document constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. It should therefore not be used as the sole basis for any investment or other decision. The use of or access to this document or content by any person does not create a fiduciary relationship between such person and Milltrust International LLP. The sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this document before making any decisions based on such information or other content rests with the user and their professional advisers. Notice to US investors: The shares of Milltrust International Managed Investments ICAV have not been registered under the 1933 Securities Act or under the 1940 Act; however, the company takes advantage of the 3(c)7 exemption and shares are available to 3(C)(1) US “qualified purchasers” and those qualifying under Reg D. Distribution activity in the US is undertaken by Silverleaf Partners LLC, a registered broker-dealer based in New York. Beyond providing initial capital for the companies we invest in, Milltrust may also leverage its extensive network to support our portfolio companies on a commercial basis with additional capital raises as they grow. Whether through introductions to potential investors, strategic partnerships, or other value-add services, we are committed to helping our portfolio companies succeed. Milltrust may receive compensation for services rendered to this company.